FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, particularly to an antibody which specifically binds to human HLA/NY-ESO, or a binding fragment thereof, to a bispecific antibody, a pharmaceutical composition containing said antibody, as well as to methods of producing said antibodies. Also disclosed is a polynucleotide coding said antibody or a fragment thereof, a polynucleotide coding said bispecific antibody, as well as a cell and a vector containing said polynucleotides.
EFFECT: invention is effective for preventing or treating cancer with cells expressing HLA-A2/NY-ESO.
30 cl, 199 dwg, 15 tbl, 23 ex
| Title | Year | Author | Number |
|---|---|---|---|
| T-CELL RECEPTORS RECOGNIZING R175H OR Y220C MUTATION IN p53 | 2020 |
|
RU2830061C2 |
| NGF ANTAGONISTS FOR MEDICAL USE | 2020 |
|
RU2829812C2 |
| IL4 RECEPTOR ANTIBODIES FOR USE IN VETERINARY SCIENCE | 2019 |
|
RU2837141C2 |
| EMBODIMENTS OF IGG-Fc FOR USE IN VETERINARY SCIENCE | 2018 |
|
RU2814952C2 |
| VERSION FC AND ITS PRODUCTION | 2021 |
|
RU2828852C1 |
| FUSED MOLECULES DERIVED FROM CHOLIX-TOXIN FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE LOADS | 2015 |
|
RU2723178C2 |
| TUMOR-TARGETING AGONIST CD28 ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2837821C1 |
| TRISPECIFIC AND/OR TRIVALENT BINDING PROTEINS USING CROSSOVER FORMAT WITH DOUBLE VARIABLE DOMAIN (CODV) FOR TREATING INFECTION CAUSED BY HIV | 2020 |
|
RU2820164C2 |
| FUSED PROTEIN CONSTRUCTS FOR COMPLEMENT-RELATED DISEASE | 2019 |
|
RU2824402C2 |
| POLYVALENT AND POLYSPECIFIC GITR-BINDING FUSED PROTEINS | 2016 |
|
RU2753439C2 |
